Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Intercell AG (VSE: ICLL)

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships, including with a number of pharmaceutical companies, with GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Romark. The Company’s pipeline of investigational products includes a Pseudomonas aeruginosa vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase I/II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), a vaccine candidate for Pneumococcus (Phase I) as well as a combination treatment approach for Hepatitis C (Phase II). A vaccine candidate against infections with C. difficile has entered Phase I clinical trials in 2010. In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”). *


Period Start 1998-01-01 established
Period End 2013-05-28 renamed
  Group Valneva (Group)
  Today Valneva Austria GmbH
  Successor Intercell Austria AG
Product Industry vaccine
Persons Person Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
  Person 2 Kandera, Reinhard (Hookipa Biotech 201704– CFO before Valneva CFO + Intercell CFO + Deutsche Bank AG)
Region Region Wien (Vienna)
  Country Austria
  Street 3 Campus-Vienna-Biocenter
  City 1030 Wien
  Tel +43-1-20620-0
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2011-03-01)
  Currency EUR
  Annual sales 35,665,000 (revenues (2012) 2012-12-31)
  Profit -25,337,000 (2012-12-31)
  Cash 44,933,000 (2012-12-31)
    * Document for �About Section�: 
Record changed: 2017-04-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Valneva (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top